Drug news
IQWiG finds limited effect of Vyndaqel (Pfizer)in TTR-FAP
The German Institute for Quality and Efficiency in Health Care (IQWiG) has assessed Vyndaqel (tafamidis)from Pfizer at the request of the Federal Joint Committee. Only one of the two relevant studies (Fx-005) provided reliable data - and only for patients with a particular genetic defect (Val30Met). The second study (Fx1A-201) in adults with different genetic defects was not controlled, i.e. here the effect of tafamidis was not directly compared with another treatment. It remains unclear how the results of the reliable study can be applied to the patients with genetic defects other than Val30Met.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.